Merck & Co.
Tracked across 45 events · 2024 articles · First seen Feb 12, 2025 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Developer and manufacturer of Lipfendra; approval boosts its cardiovascular pipeline and revenue prospects.
Jul 16, 2026 · 93 articles
Tech
Moderna and Merck & Co. announced on August 19, 2026, that their personalized mRNA cancer vaccine, Intismeran, combined with Merck's immunotherapy drug Pembrolizumab, met its primary and secondary goals in a Phase 3 trial for…
Impact: Merck is the partner in developing the vaccine and provides Pembrolizumab, which is combined with the vaccine. The trial success offers a new growth avenue as Pembrolizumab faces patent expiration, and its stock rose about 11%.
Aug 19, 2026 · 102 articles
Regulatory
Impact: Merck & Co. struck a deal to cut prices, committing to sell its diabetes drugs Januvia, Janumet, and Janumet XR at 70% off list prices directly to US consumers and pledging $70 billion in US R&D and manufacturing investments.
Dec 19, 2025 · 7 articles
Business
Impact: MSD (Merck & Co., Inc., Rahway, New Jersey, USA) is partnering with the United Arab Emirates — Department of Health – Abu Dhabi (DoH)>>> to create a regional logistics hub, which will enhance its product distribution and market access in the region.
Jun 24, 2026 · 7 articles
International
Impact: Merck & Co. is under investigation by the United States — House Select Committee on the Chinese Communist Party for its clinical trials in China, particularly in China — Xinjiang and at military hospitals, raising concerns about national security and ethics. This exposes Merck & Co. to potential reputational damage and regulatory scrutiny.
Apr 20, 2026 · 8 articles
Business
Impact: Merck & Co. is collaborating with The Hashgraph Association to integrate its M-Trust physical authentication technology, aiming to meet EU product transparency regulations and enhance its supply chain solutions.
Jun 09, 2026 · 7 articles
Business
Impact: Merck & Co., through its subsidiary MSD, will provide pembrolizumab (Pembrolizumab) for the Phase Ib clinical trial. This collaboration expands the potential applications of Pembrolizumab and strengthens its market position.
May 26, 2026 · 6 articles
Tech
Impact: As the manufacturer of pembrolizumab (Keytruda), Merck & Co.>>> benefits from the combination therapy's success, as it reinforces the drug's role as a standard of care and expands its potential market in combination with intismeran. The positive results could lead to continued strong sales for pembrolizumab.
Jun 01, 2026 · 6 articles
Tech
Impact: As the licensee for sac-TMT outside Greater China, the positive clinical trial results for sac-TMT in combination with its drug pembrolizumab (KEYTRUDA) validate its investment and expand its oncology portfolio.
May 30, 2026 · 14 articles
Tech
Impact: Merck & Co. is the manufacturer of pembrolizumab and reached a commercial agreement with United Kingdom — National Health Service England, leading to the drug's approval and availability.
Jun 25, 2026 · 6 articles
Business
Impact: Merck & Co. is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Regulatory
Impact: Merck & Co. is the developer of Pembrolizumab, and the expanded FDA approval of the companion diagnostic test will likely increase the patient pool for its anti-PD-1 therapy.
Jun 02, 2026 · 7 articles
Domestic
On August 10, 2026, President Donald Trump signed an executive order overhauling the U.S. childhood vaccine schedule. The order reduces the number of universally recommended vaccines from 18 to 11 diseases, recommends splitting the combined…
Impact: Manufacturer of the MMR vaccine, stated no scientific benefit to splitting it. Faces potential regulatory and market pressure if separate vaccines are developed, but currently no immediate financial impact.
Aug 10, 2026 · 235 articles
Tech
Impact: Merck & Co.>>>'s immunotherapy Keytruda is mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
Business
Impact: Merck & Co. is a prominent company in the maleic anhydride market, influencing its development and growth.
Jun 02, 2026 · 7 articles
Accidents
Impact: Merck & Co. is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Regulatory
Impact: Merck & Co. benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Pembrolizumab therapy, potentially increasing the drug's market reach.
Jun 11, 2026 · 6 articles
Domestic
Impact: Merck & Co., a hepatitis B vaccine maker, expressed deep concern over the ACIP's vote, and its shares closed down 1.2% on Friday.
Dec 05, 2025 · 7 articles
Business
Impact: Merck is participating in the Kinaxis conference as a speaker, sharing insights on navigating disruption and improving operational outcomes in supply chain management.
May 28, 2026 · 6 articles
Business
Impact: Merck & Co. saw its stock price rise, contributing to the gains in the Dow Jones Industrial Average.
May 20, 2026 · 12 articles
Accidents
Impact: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.
May 18, 2026 · 505 articles
Tech
Impact: Merck & Co.'s approved vaccine Ervebo for the Zaire strain of Ebola is referenced as a technological precedent for IAVI's Bundibugyo vaccine candidate.
May 22, 2026 · 36 articles
Tech
Impact: Merck & Co. developed Ervebo, the only licensed Ebola vaccine, which the World Health Organization reviewed but recommended against deploying outside research settings for the Bundibugyo strain due to limited evidence.
May 28, 2026 · 6 articles
Business
Impact: Merck is mentioned as the former employer of Paul Reichert, highlighting its role in pharmaceutical innovation.
Jul 08, 2026 · 6 articles
Domestic
Impact: Merck & Co. posted strong gains, contributing to the positive performance of Dow components.
May 28, 2026 · 6 articles
Tech
Impact: Merck & Co. is mentioned as a client of Benevity, utilizing its grant management services.
Jun 04, 2026 · 6 articles
Regulatory
Impact: Merck supported Gilead's appeal, benefiting from the ruling that limits negligence exposure for drugmakers.
Aug 03, 2026 · 6 articles
Business
Impact: Merck's Lipfendra, the first FDA-approved PCSK9 pill, competes with Scribe's STX-1150. Scribe's epigenetic approach may differentiate it.
Jul 06, 2026 · 25 articles
Business
Impact: Merck & Co. acquired Terns Pharmaceuticals, where Andrew Gengos previously worked.
Jun 15, 2026 · 6 articles
Business
Impact: Merck & Co. is mentioned as a reference for its successful Phase 3 STELLAR study, which Gossamer Bio management cited in comparison to their own trial.
Apr 01, 2026 · 228 articles
+ 15 more events
View on Dashboard
100
Merck & Co. announced trial resultsModerna Merck mRNA...
90
Merck & Co. saw shares riseModerna Merck mRNA...
80
Merck & Co. plans to file for approval United States — Food and Drug AdministrationModerna Merck mRNA...
70
Merck & Co. developed personalized vaccineModerna Merck mRNA...
60
Merck & Co. criticized orderTrump signs childhood...
60
Merck & Co. criticized order Donald TrumpTrump signs childhood...
60
Merck & Co. faced patent lossModerna Merck mRNA...
+ 32 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Merck & Co. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard